News

Ohio State, Nationwide Children’s Hospital Partner with ENTvantage Diagnostics to Bring Rapid Sinusitis Diagnostic Test to Physicians

First-of-its-kind diagnostic kit for in-office, rapid diagnosing of bacterial sinusitis 

COLUMBUS, Ohio, and AUSTIN, Texas-The Ohio State University, through the Ohio State Innovation Foundation, and Nationwide Children’s Hospital announced the signing of an exclusive, world-wide agreement with ENTvantage Diagnostics Inc. licensing a technology for rapid diagnosing of bacterial sinusitis. The jointly-created technology will be the foundation for ENTvantage Diagnostics Inc. to develop a diagnostic kit based on this technology to better equip physicians with additional information when making a bacterial sinusitis diagnosis.

The technology was developed as a result of the research collaboration between The Ohio State University and Nationwide Children’s Hospital. Subinoy Das, M.D. and Lauren O. Bakaletz, Ph.D., joined forces to create the diagnostic technology. Das is the former Director of The Ohio State University Sinus and Allergy Center and is now an adjunct Assistant Professor at The Ohio State University. In addition, he is a Research Associate of the Center for Microbial Pathogenesis in The Research Institute at Nationwide Children’s Hospital.  Bakaletz is the Director of the Center for Microbial Pathogenesis in The Research Institute at Nationwide Children’s. She is a Professor in the Departments of Pediatrics and of Otolaryngology at The Ohio State University College of Medicine

Determining the primary cause of sinusitis remains a clinical challenge for physicians. Different kinds of medication are often given to a patient until a specific medication is effective in improving the sinusitis condition. The diagnostic kit will enable physicians to take a sample swab from a patient’s nose, perform a rapid analysis, and have the results of the infection available in five minutes.

“Many patients are being prescribed antibiotics that they do not need or do not optimally treat the underlying pathogenic bacteria because there is a lack of definitive office-based diagnostic tests for this infection,” said Das. “This assay kit will help physicians understand the underlying bacterial cause of sinusitis in their office and allow better selection of antibiotics to treat patients. In addition to more efficient treatment, the diagnostic kit will also aid in reducing the number of antibiotic resistant infections and complications.”

“Our research serves as the foundation for this diagnostic test by demonstrating the specific bacterial protein profiles associated with chronic sinusitis. With the identification of these biomarkers, tests now can be developed to determine the presence and type of pathogenic bacteria in the upper respiratory tract,” Bakaletz explained. “Seeing our research result in a positive impact on physician practice, and more importantly on patient health, is the aspiration of every medical scientist.”

Nationwide Children’s Hospital and Ohio State have a long-standing collaborative history and continue to work together on several fronts, one of which includes commercializing technologies. Both organizations have an equity position in ENTvantage Diagnostics Inc.

ENTvantage was founded by serial medical device entrepreneurs Joe Skraba and Rick Hawkins who bring more than 50 years of collective experience in commercialization of a broad range of medical devices, pharmaceuticals and biotech products.

“Dr. Das and Dr. Bakaletz are thought leaders in their disciplines and the technology they created will truly change the diagnostic capabilities for bacterial sinusitis,” said Skraba. “Collaborating with Nationwide Children’s Hospital and Ohio State was a logical decision for ENTvantage.”

Austin-based ENTvantage plans to commercialize diagnostic tests to improve the diagnosis of illnesses of the ear, nose and throat by providing rapid, in-office diagnostic test kits to physicians world-wide.

“The lack of diagnostic tools has led physicians to over prescribe antibiotics to treat sinusitis when they are not needed, we know that we can provide physicians with timely information to better diagnose the underlying cause of these illnesses and lead to better management of sinusitis,” said Joe Skraba, the President & CEO of ENTvantage.

The implications of ENTvantage’ s diagnostic kit go well beyond bacterial sinusitis.

“The same pathogens that cause bacterial sinusitis, also cause illnesses in other areas of the body, we believe we can extend this technology to identify these bacterial pathogens and lead to improved patient care, reduction of treatment costs and a reduction in the growing worldwide epidemic of antibiotic resistant infections,” said Skraba.

###

About The Ohio State University:

Ohio State is a dynamic community of diverse resources, where opportunity thrives and where individuals transform themselves and the world. Founded in 1870, The Ohio State University is a world-class public research university and the leading comprehensive teaching and research institution in the state of Ohio. With more than 63,000 students (including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80 centers, and 175 majors, the university offers its students tremendous breadth and depth of opportunity in the liberal arts, the sciences, and the professions. 

About Nationwide Children’s Hospital:

Ranked in all 10 specialties in “U.S. News & World Report’s 2013-14 Best Children’s Hospitals” and among the Top 10 on Parents magazine’s 2013 “Best Children’s Hospitals” lists, Nationwide Children’s Hospital is one of the nation’s largest not-for-profit freestanding pediatric healthcare networks providing care for infants, children, adolescents and adult patients with congenital disease. As home to the Department of Pediatrics of The Ohio State University College of Medicine, Nationwide Children’s Hospital faculty train the next generation of pediatricians, scientists and pediatric specialists. The Research Institute at Nationwide Children’s Hospital is one of the top 10 National Institutes of Health-funded free-standing pediatric research facilities in the U.S., supporting basic, clinical, and translational and health services research at Nationwide Children’s Hospital.

About ENTvantage:

ENTvantage Diagnostics Inc. based in Austin TX, develops and markets rapid, in-office diagnostic tests that provide primary care and ENT physicians with timely information on the causes of ear, nose and throat illnesses.  The company’s first products will assist physicians to accurately diagnose bacterial sinusitis and lead to a reduction in inappropriate antibiotic prescriptions.

Contact:

Melanie Baker

Marketing and Communication Manager

The Ohio State University

Technology Commercialization Office

614.292.9839 (Office)

baker.756@osu.edu

Share This!

The Ohio State University and University of Michigan Partner with Industry to Bring Oral Cancer-Fighting Patch to Patients

Ohio-based Venture Therapeutics Named Industry Partner

COLUMBUS, Ohio – The Ohio State University and the University of Michigan have signed an exclusive worldwide agreement with Ohio-based Venture Therapeutics, Inc., to form a new company to develop and commercialize a pharmaceutical technology targeted for the treatment of precancerous oral lesions. These lesions are currently managed by invasive surgery and approximately a third of these lesions will reoccur after surgery.

Previously published data shows that about 30 percent of the higher grade precancerous oral lesions progress to oral cancer, specifically oral squamous cell carcinoma. This type of cancer is particularly devastating to patients because treatment entails removal of facial and mouth structures essential for esthetics and function. The National Cancer Institute estimates that 42,440 Americans will be diagnosed with oral cancer and over 8,390 oral cancer related deaths will occur in 2014.

The pharmaceutical technology developed by researchers at The Ohio State University (OSU) College of Dentistry with secondary appointments at the OSU Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and the University of Michigan addresses a significant unmet need related to the prevention of oral cancer. Precancerous oral lesions can be seen and touched by patients, so this easy access to the lesion allows the use of local delivery formulations in an oral patch to directly treat the disease without causing adverse side effects.

“This type of collaboration, involving multiple university partners with strong industry support, is increasingly essential to expedite the discovery, development and delivery of more targeted cancer therapies.  There is no routine cancer, and today, it takes the collective minds across disciplines, institutions and industry to move the field forward,” says Michael Caligiuri, MD, director of The Ohio State University Comprehensive Cancer Center and chief executive officer of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

“Ultimately, these collaborations can be the catalyst for new, more effective cancer treatments, leading to better outcomes, faster responses, fewer side effects and more hope for cancer patients everywhere,” said Caligiuri.

These technologies were developed by a team of university-based researchers who work extensively with the affected patient population and actively explore new drug delivery methods such as the oral patch.

Susan R. Mallery DDS, PhD, professor and interim chair of the division of oral pathology and radiology at the Ohio State

College of Dentistry and member of the OSUCCC – James Molecular Carcinogenesis/Chemoprevention Research

Program, worked alongside Steven P. Schwendeman, PhD, Ara G. Paul Professor and Chair of the Department of Pharmaceutical Sciences, Professor of Biomedical Engineering, at the Biointerfaces Institute, University of Michigan, and his former assistant research scientist, Kashappa Goud Desai, PhD, to invent this breakthrough technology.

“The oral patch sidesteps any toxicity issues, which have historically been a problem with conventional treatments,” said

Mallery. “This technology delivers an excellent chemopreventive compound directly to the precancerous tissues.”

“Dr. Mallery and I have collaborated for years on translational research projects,” said Schwendeman.  “It is very gratifying to see our efforts progress past the preclinical state and into clinical trials where we can directly help patients.”

The College of Dentistry at Ohio State saw great things for the collaboration between the two universities.  “Having two College of Dentistry faculty members from Ohio State engage with researchers from the University of Michigan resulted in a very innovative approach that will dramatically improve patient care and outcomes,” said Dean Patrick Lloyd, College of Dentistry. “Conducting the clinical trials for this innovation at Ohio State’s College of Dentistry is very promising for the technology and prospective patients, and beneficial to both universities on a national level.”

Drug Development and Commercialization Partnership Formed
Ohio State, through the Ohio State Innovation Foundation and the university’s Drug Development Institute, and the University of Michigan licensed the intellectual property to the newly formed Sirona Therapeutics.

In this unique business model, Ohio State and Venture Therapeutics will work together throughout the entire drug development process, including commercialization of the technology. Venture Therapeutics will be responsible for the drug development activities including formulation development, clinical trial batch manufacture, clinical trial and bio-analytical activities and regulatory affairs. Ohio State will provide assistance with transfer of intellectual property, clinical trials, and recruitment of patients, patient biopsies, surgical suites, and pharmacokinetic analysis.

“This agreement with Venture Therapeutics and the creation of Sirona Therapeutics is a great example of a collaboration that provides long-term value for the university, central Ohio, and patients,” said Tim Wright, vice president of Technology Commercialization and Founder of the Drug Development Institute at Ohio State.  “This agreement is in alignment with one of the university’s research priorities, health and wellness, with the ultimate goal of moving this technology through commercialization thereby improving lives.”

Venture Therapeutics, with offices and laboratories in Columbus and New Albany, was co-founded by Peter Stoelzle and Michael Medors, who have more than 50 years of combined experience in the pharmaceutical industry. This alliance will allow continued faculty participation in the advancement of the technology, as well as integration of core university facilities during the next phase of human clinical trials.

“The management team of Venture Therapeutics has proven experience in quickly and efficiently delivering critical care therapeutics to commercial markets. These skill sets are complementary to Ohio State’s proficiency in the discovery and clinical development of human therapeutics,” said Stoelzle.

“Collaboration will be efficient, given that both Venture Therapeutics and the university are located in the Central Ohio area. This can help compress development timelines and enable patients more rapid access to the technology.” said Stoelzle.

About The Ohio State University

Ohio State is a dynamic community of diverse resources, where opportunity thrives and where individuals transform themselves and the world. Founded in 1870, The Ohio State University is a world-class public research university and the leading comprehensive teaching and research institution in the state of Ohio. With more than 63,000 students (including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80 centers, and 175 majors, the university offers its students tremendous breadth and depth of opportunity in the liberal arts, the sciences, and the professions.

About the University of Michigan

The University of Michigan spends over $1.3 billion per year on its wide-ranging research initiatives, making it one of the largest, most successful academic research institutions in the world. U-M Tech Transfer, the University unit responsible for transferring research discoveries to business and venture partners, launches an average of 10 start-ups, and signs over 100 agreements with businesses annually. More on U-M Tech Transfer, including an up-to-date list of technologies available for commercialization, can be found at the U-M Tech Transfer website, http://www.techtransfer.umich.edu.

About The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Ohio State’s Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) strives to create a cancer-free world by integrating molecular- and genetic-based discoveries into patient care, a strategy that leads to better prevention, detection and treatment of individual cancers. OSUCCC – James is one of only 41 National Cancer Institute-designated Comprehensive Cancer Centers and one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials. More than 300 cancer researchers from 12 of Ohio State’s 14 colleges collaborate across research programs and disciplines to make some of the world’s most game-changing discoveries. In December 2014, The Ohio State University will open the doors of the new James Cancer Hospital and Solove Research Institute, a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. The new James will help revolutionize cancer prevention and care by enabling world-class oncologists and researchers to work side-by-side to solve the mysteries of this disease.

About Venture Therapeutics

Venture Therapeutics is a drug development company focused on developing, manufacturing and delivering innovative human therapies for unmet medical needs. Its management team has a proven record of success, having received FDA approval for more than 50 drug products.  These products include injectable, ophthalmic, otic, oral, and topical dosage forms.

About Sirona Therapeutics

Sirona Therapeutics, Inc. is a newly formed company among Venture Therapeutics, Inc., Ohio State Innovation Foundation and The Regents of the University of Michigan created to develop and commercialize a drug delivery technology to treat precancerous oral lesions.

###

Media Contacts: Amanda J. Harper, Director of Media Relations, The OSUCCC–James, 614-685-5420 (direct), 614-293-3737 (central media line) or Amanda.Harper2@osumc.edu

Melanie Baker, Marketing and Communications Manager, Ohio State Technology Commercialization Office, 614-292-9839 or baker.756@osu.edu.

Share This!

Ohio State Partners with MedVax Technologies, Inc. to Bring a Cancer Peptide Vaccine to Patients

COLUMBUS, Ohio, and MIAMI, Florida–The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking cancer peptide vaccine technologies.

The anticancer vaccine technologies are designed for the treatment and prevention of cancers associated with the HER2 protein. These include breast, ovarian, lung, colon and pancreatic cancers, and gastrointestinal stromal tumors. The commitment by MedVax will allow innovative clinical trials for various cancers to be conducted in the near future.

Development of these technologies, which took decades of research, was led by Pravin T. P. Kaumaya, PhD, a cancer researcher with The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute (OSUCCC-James) Innate Immunity Program.

The work has been funded by nearly $15 million in grants from the National Cancer Institute and the National Institutes of Health (NIH/NCI CA 84356, NIH/NCI CA 094555, NIH/NCI CA 135608, and NIH/NIH CA 82869). Additional funding was provided by Pelotonia and Fore Cancer Research.

“We have developed and have conducted two NCI-funded, FDA-approved clinical trials at The OSUCCC – James,” says Kaumaya who also serves director of the Division of Vaccine Development and Peptide and Protein Engineering laboratory in the department of obstetrics and gynecology at the Ohio State Wexner Medical Center and as a professor of obstetrics and gynecology, molecular and cellular biochemistry, and microbiology at Ohio State’s College of Medicine.

“Both trials have shown the candidate vaccines to be safe, and several metastatic cancer patients have obtained clinical benefit with little toxicity,” says Kaumaya, who led the development of the trial protocol, as well as development of the vaccine.

“Stimulating the body’s immune system to fight cancer is a Holy Grail of cancer research,” says Michael A. Caligiuri, MD, John L. Marakas Nationwide Insurance Enterprise Foundation Chair in Cancer Research, director of The Ohio State University Comprehensive Cancer Center and CEO of The James Cancer Hospital and Solove Research Institute.

“These vaccine technologies developed by Dr. Kaumaya and his collaborators are a giant step in that direction. Our hope is that this partnership with MedVax Technologies will complete this effort and successfully bring these anticancer vaccines into the clinic.”

MedVax Technologies, Inc. was founded by biotech entrepreneur Robert Brooks, JD, who has extensive investment knowledge and experience in the life-science industries and is the company’s chief executive officer.

“This licensing agreement with Ohio State of a chimeric HER2 Peptide Vaccine can translate into transformational changes for the treatment and prevention of several human cancers,” Brooks says. “Partnering with Ohio State was a strong positive decision for MedVax.” As part of the license agreement, MedVax has committed to fund an efficacy trial at Ohio State in breast, ovarian and gastric cancers. The phase 1b clinical trial will involve 30-60 patients per tumor type.

“Health and Wellness” is at the forefront of Ohio State’s research agenda and identified as one of the university’s primary areas for investment and growth. Commercializing this research area has great potential for current and future patients,” says Tim Wright, vice president of technology commercialization at Ohio State.

“The agreement with MedVax to commercialize Dr. Kaumaya‘s research is one great stride further in getting these innovations into the global marketplace,” adds Wright. “These technologies possess the potential to permanently change patient lives; advancing them from the lab to the clinic would be a major win in the fight against cancer. A win everyone is working hard to see happen.”

###

About MedVax Technologies, Inc.

MedVax Technologies, Inc. is a biopharmaceutical company focused on discovery and commercializing cancer immunotherapy treatments.

About The Ohio State University Comprehensive Cancer Center

Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as ranked by U.S. News & World Report.

About The Ohio State University

The Ohio State University is a dynamic community of diverse resources, where opportunity thrives and where individuals transform themselves and the world. Founded in 1870, Ohio State is a world-class public research university and the leading comprehensive teaching and research institution in the state of Ohio. With more than 63,000 students (including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80 centers and 175 majors, the university offers its students tremendous breadth and depth of opportunity in the liberal arts, the sciences and the professions. 

 

CONTACTS:

Melanie Baker

Marketing and Communication Manager
Technology Commercialization Office
614.292.9839 Office

baker.756@osu.edu

Amanda J. Harper

Director, Media Relations

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute

O: 614-685-5420

C: 513-659-6847

amanda.harper2@osumc.edu

 

Robert K. Brooks, JD

Chief Executive Officer

MedVax Technologies, Inc.

Tel. (305) 371-2301

Robert.Brooks@MedVax.net

Share This!

Ohio State Partners with Signet Accel LLC

Ohio State Partners with Signet Accel LLC to Accelerate Health Care Data Sharing Worldwide

Agreement includes largest up-front licensing fee

 COLUMBUS, Ohio - The Ohio State University today announced the signing of an exclusive worldwide agreement with a new company formed by Signet Enterprises: Signet Accel LLC. The new company will license a portfolio of cutting-edge Ohio State-developed software technologies for health care data sharing and advanced analytics through the Ohio State Innovation Foundation.

Signet Accel will provide technology solutions in a variety of health care and life sciences areas. The company’s applications will enable data sharing and analytics ranging from improving the design and conduct of clinical trials to supporting quality improvement in health care delivery in the United States and throughout the world.

The agreement between Ohio State and Signet Enterprises is projected to generate several million dollars in licensing fees during the life of the agreement, as well as equity for the university. It includes the largest up-front licensing payment to Ohio State — $275,000 that already has been received from Signet Enterprises. These fees will result in direct benefit to the university and the College of Medicine.

“Most research and industry sectors see the value of leveraging big data and realize how instrumental the analysis is to the progress of our global society,” Provost Joseph Steinmetz said. “The foundation of the university’s first Discovery Themes initiative is comprised of research involving data analytics. Ohio State continues to focus on data analytics and providing opportunities for students and researchers to further explore this ever-expanding field.”

While the focus of the new company is global, the company plans to locate in central Ohio near the Ohio State campus, allowing it to take advantage of a highly skilled biomedical and computational work force being trained at the university.

Signet Accel’s technology will enable the rapid and efficient analysis of all types of health care data, allowing providers, patients and health care companies to enhance wellness and make treatment decisions based on the most current, accurate evidence.

The technologies involved in the venture were developed during the past decade by the Department of Biomedical Informatics at The Ohio State University College of Medicine, led by Philip R.O. Payne, chair of the department. Payne and Peter J. Embi, vice chair of the department, are the Ohio State faculty members who serve as co-founders of the new company.

“Our innovative technology platform allows health care organizations to share and analyze data in ways that have not previously been possible, eliminating the technical and regulatory challenges that result from trying to centralize sensitive information and enabling those entities to generate critical insights from distributed and complex data in a highly secure and on-demand manner,” Payne said.

Tim Wright, vice president of Technology Commercialization at Ohio State, called the collaboration a great example of an agreement that provides long-term value for the university and global society. “Our goal is to support Ohio State’s researchers in the commercialization process,” Wright said.

Signet Enterprises has widespread experience in business development and project and corporate financing. Signet Chairman Anthony Manna is an Ohio State alumnus.

“Signet and Ohio State share a passion for advancing faculty-developed technologies into the global marketplace,” Manna said. “The team from Signet, led by Aaron Bates (COO) and George Ammar (CFO), worked with Ohio State to advance this technology and develop a model that Ohio State and Signet will use for future opportunities.  As an Ohio State alumnus, I am very proud of this collaboration that also benefits my alma mater.”

Dave Billiter, director of the Informatics Core at The Research Institute at Nationwide Children’s Hospital, recently accepted the position of executive vice president of Signet Accel and will join the team at end of March.

About The Ohio State University

The Ohio State University is a dynamic community of diverse resources, where opportunity thrives and where individuals transform themselves and the world. Founded in 1870, Ohio State is a world-class public research university and the leading comprehensive teaching and research institution in the state of Ohio. With more than 63,000 students (including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80 centers and 175 majors, the university offers its students tremendous breadth and depth of opportunity in the liberal arts, the sciences and the professions.

About Signet Enterprises:

Signet Enterprises is the 4th largest private equity firm in Ohio. Signet Enterprises unites an entrepreneurial vision with the experience to turn opportunities into realities. With decades of experience, Signet’s principals provide highly specialized knowledge and expertise in distinct disciplines including real estate development, international initiatives, start-ups, technology, and mergers & acquisitions. Signet Enterprises includes Signet Development, Signet Ventures and Signet International.

Share This!

TechColumbus and The Ohio State University Announce Technology Concept Fund

$1 Million Evergreen Fund to Commercialize Ohio State Technology

Columbus, OH (December 19, 2013) Innovations with ties to The Ohio State University will get a financial boost from the new Technology Concept Fund, LLC. The million-dollar fund includes investments from Ohio State and Ohio Third Frontier. The Technology Concept Fund will be managed by TechColumbus.

“The Technology Concept Fund will provide critical investment capital at the earliest stage and is specifically for Ohio State innovations,” said Tom Walker, TechColumbus CEO. “This fund will be an accelerator for investors and entrepreneurs who have formed companies around technologies licensed from Ohio State.”

Companies eligible for investment will have a fully executed license or an option to license the technology from Ohio State and will be clients of TechColumbus. Industry focus includes advanced materials, alternative energy, information technology and life sciences.

“The researchers at Ohio State are discovering and developing technologies that can have a significant impact on the world around us,” said Tim Wright, vice president of technology commercialization for Ohio State. “This fund will provide the essential capital support needed to advance these technologies to the next stage and ultimately move them to the market for the good of society.” Investments by the Technology Concept Fund are likely to be among the first dollars that come into these projects. While it isn’t explicitly required, it is desirable for the company to present additional validation by having additional funding from the founding entrepreneur, grants, strategic partners and/or other sources of capital.

TechColumbus and Ohio State’s Technology Commercialization Office are working proactively to identify investment opportunities. “We have a strong pipeline and two near-term deals that are in active due diligence,” Walker said.

The Concept Fund will be evergreen in nature, so that successful investments by the fund will replenish the capital available to be deployed. Investments will typically be in the form of convertible debt with a valuation cap. “We’re excited for this fund to come to fruition. TechColumbus is a logical and capable steward for this fund and a great partner to aid in advancing the university’s promising technologies,” Wright said.

The Technology Concept Fund extends TechColumbus’ continuum of capital, making it possible to invest in the youngest ventures. Additional funding options will be announced in the coming weeks.

About TechColumbus

TechColumbus, Columbus, OH, helps build and accelerate great companies by providing expert advice, access to capital, and business growth connections. We help grow the entrepreneurial ecosystem of Central Ohio by connecting entrepreneurs, advisors, resource providers, public sector entities, academia, and corporations who share startup passion. TechColumbus manages a continuum of investment funds

made possible by the participation of Ohio Third Frontier and other strategic partners. Hundreds of technology entrepreneurs and startup companies come to TechColumbus each year to receive the services and funding they need to grow into sustainable, profitable businesses. http://www.techcolumbus.org

About The Ohio State University

Ohio State is a dynamic community of diverse resources, where opportunity thrives and where individuals transform themselves and the world. Founded in 1870, The Ohio State University is a world-class public research university and the leading comprehensive teaching and research institution in the state of Ohio. With more than 63,000 students (including 57,000 in Columbus), the Wexner Medical Center, 14 colleges, 80 centers, and 175 majors, the university offers its students tremendous breadth and depth of opportunity in the liberal arts, the sciences, and the professions.

Share This!

Six Ohio State Faculty Among the 2013 Class of AAAS Fellows

Group includes executive dean of the College of Arts and Sciences

COLUMBUS, Ohio – Six Ohio State University faculty specializing in disciplines ranging from cancer treatment to number theory have been elected as Fellows of the American Association for the Advancement of Science (AAAS), honored by their peers as significant contributors to the scientific community.

In all, 388 association members have been elected Fellows this year in recognition of their scientifically or socially distinguished efforts to advance science or its applications. New Fellows will be welcomed in a ceremony at the AAAS annual meeting in Chicago in February.

Founded in 1848, AAAS is the world’s largest general scientific society. The tradition of AAAS Fellows began in 1874.

“The consistent recognition of Ohio State scientists at this level speaks to the exceptional quality of our faculty and their important contributions in their disciplines,” said Interim President Joseph A. Alutto. “Their talent and expertise in the classroom and their research endeavors directly benefit our students, the state of Ohio, and beyond.”

Including this year’s class, Ohio State has approximately 200 AAAS Fellows – a sign of the depth and breadth of scientific expertise on the university faculty, according to Caroline Whitacre, vice president for research.

“We celebrate the recognition of these individuals by their peers and applaud the scholarship and creativity they bring to their respective fields,” Whitacre said. “From awards received, to students inspired and global challenges addressed, these Ohio State researchers are leading discovery, advancing knowledge and finding creative and collaborative ways to transform lives across the globe.”

Ohio State’s newest AAAS Fellows are:

John Freudenstein, professor of evolution, ecology and organismal biology (College of Arts and Sciences); for distinguished contributions to the study of plant evolution and systematics, especially in orchids, and administrative leadership of the university’s Herbarium.

Norman Johnson, professor of evolution, ecology and organismal biology and of entomology (Colleges of Arts and Sciences and Food, Agricultural and Environmental Sciences); for distinguished contributions to systematic studies of insects and for developing innovative computational tools for cataloging the distribution, history and status of the world’s biodiversity.

James Kinder, professor of animal sciences and of veterinary preventive medicine (Colleges of Food, Agricultural and Environmental Sciences and Veterinary Medicine); for distinguished contributions in reproductive endocrinology research, and as an administrator in the College of Food, Agricultural and Environmental Sciences.

David Manderscheid, executive dean of the College of Arts and Sciences, vice provost for arts and sciences and professor of mathematics; for distinguished contributions to number theory, for outstanding service on national committees and conference organization, and for exceptional commitment to the advancement of women and minorities.

Zucai Suo, professor of chemistry and biochemistry (College of Arts and Sciences); for distinguished contributions to the field of nucleic acid enzymology, particularly for pre-steady state kinetic and protein conformational dynamic studies of DNA polymerases.

Miguel Villalona-Calero, professor of internal medicine and of pharmacology and division director of medical oncology (College of Medicine, Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute); for distinguished contributions in the field of experimental therapeutics, developing novel therapeutics and conducting clinical trials for translational research in cancer patients.

#

Contact: Emily Caldwell, (614) 292-8310; Caldwell.151@osu.edu

 
Share This!

Commercialization for Researchers Course

Commercialization for Researchers

VETBIOS 8855                  2 CREDIT HRS                   SPRING

There is a new Graduate course now offered at The Ohio State University for researchers who are interested in learning more about Commercialization!

One of the missions of the Research University is to discover and transfer knowledge for the betterment of society. Commercialization of faculty or student inventions is one recognized method for the transfer of knowledge to improve lives. Commercialization is an area of emphasis for universities and granting agencies to improve adoption of new technologies in the private sector and attain the maximal benefit of research discoveries for society.

Graduate students are likely to be involved with new discoveries and inventions in their research projects. It is necessary for graduate students to understand the purpose and methods of commercialization so that they can position their potential inventions for maximal impact. This course will be useful to graduate students in the health sciences, engineering, and physical sciences.

View course details – VETBIOS 8855

Share This!